Market Overview

UPDATE: J.P. Morgan Initiates Coverage on Dynavax Technologies Corporation with Neutral Rating

Related DVAX
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4
William Blair's Top BioPharma Stock Picks For Q1 2015
Oversight board recommends continuing Heplisav-B Phase 3 trial (Seeking Alpha)

In a report published Wednesday, J.P. Morgan & Co. initiated coverage on Dynavax Technologies Corporation (NASDAQ: DVAX) with a Neutral rating.

J.P. Morgan noted, “We are initiating coverage of Dynavax (DVAX) with a Neutral rating. Dynavax is a clinical stage biotechnology company with a focus on infectious and inflammatory diseases. The company has a number of interesting early-stage candidates in the pipeline, but the key potential value driver is the lead asset HEPLISAV, which has been submitted to the FDA for the active immunization against all subtypes of hepatitis B virus infection in adults 18-70 years of age. The Biologics License Application (BLA) has been submitted and a PDUFA date of February 24, 2013 has been set. While physician feedback leads us to believe that HEPLISAV is differentiated on the efficacy/convenience side, a recent FDA AdComm highlighted concerns on the robustness of its safety database and its overall benefit/risk profile. If granted a broad indication, HEPLISAV could be a ~$720M WW opportunity at peak, in our view. However, given the regulatory risks associated with HEPLISAV, we don't see the risk-reward profile as attractive, and thus we believe a Neutral rating is warranted. Our NPV analysis yields a valuation of $3/share.”

Dynavax Technologies Corporation closed on Monday at $2.85.

Latest Ratings for DVAX

Nov 2013McNicoll Lewis VlakUpgradesHoldBuy
Nov 2013JefferiesReiteratesBuy
Jun 2013JefferiesMaintainsBuy

View More Analyst Ratings for DVAX
View the Latest Analyst Ratings

Posted-In: J.P. Morgan & Co.Analyst Color Initiation Analyst Ratings


Related Articles (DVAX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content